A blog by Ronny Allan

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)


I’ve been wanting to write about this for some time but news in UK today made all the big newspapers. I don’t normally write about other cancers but I’ve been following this one for a while and decided to put pen to paper because it is ground-breaking.  Many people will  have heard about the new drug daraxonrasib which has taken pancreatic adenocarcinoma treatment to a new level.  The news today covered the second phase of clinical trials combining it with cytotoxic chemotherapy (in the case of this trial, GnP is a shortener of gemcitabine plus nab-paclitaxel).  When news of the daraxonrasib drug came out earlier this year, it also made the main newspapers and TV in many countries.  At that time, I noticed that many NET patients tried to post about it in my group and on my pages; and to me via messages.  I tried to avoid it explaining that on paper this is not something for pancreatic Neuroendocrine Neoplasms (Neuroendocrine Tumours or Neuroendocrine Carcinoma).  The media coverage and the clinical trials document clearly said “pancreatic adenocarcinoma” – as did this new announcement of the combo therapy above. The clinical trial document (see below) also confirms it does not include Neuroendocrine Neoplasms (“Histologically or cytologically confirmed pancreatic adenocarcinoma”)

Allowing for an element of sensationalism which the media sometimes add, I decided to write this story and pass it on (and not only to counter further attempts to link this is Neuroendocrine Cancer) but for hope that scientists are working on many new trials and drugs that can make a difference.  This one stands out when you see the pancreatic cancer statistics below.

What is daraxonrasib?

Daraxonrasib is a KRAS inhibitor treatment, which works by locking on to and shutting off certain mutations found in most pancreatic cancers. These mutations drive tumour growth.  There are hopes the treatment could work for dozens of other cancers because they can have similar mutations. Around 90% of people with pancreatic ductal adenocarcinoma (the most common form of pancreatic cancer) have a change (mutation) in a gene called KRAS. It’s an oral treatment taken daily in pill form.  You may hear it called Rasonque®, which is the brand name.

Approvals to date.

US FDA approved it in August 2026, EU approved it November 2026.  In UK, currently only available in clinical trials at 11 centres (see link below). The UK tends to follow EU for approvals (mostly) but there is no confirmed UK regulatory submission or official launch date available.

Cancer Research UK are calling it the biggest breakthrough in pancreatic cancer treatment for decades – a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers.  Highlights from the media stories. 

  • Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy (Gemcitabine and nab-paclitaxel (GnP) in early medical trials.

  • Tumours stopped growing in almost all of the 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. The pill targets a protein called KRAS, nicknamed the “Death Star” because it is so difficult to attack with drugs. More than nine in 10 pancreatic tumours carry a mutation in the gene that makes KRAS

  • But doctors stress it is a long way from knowing how long it might keep the disease at bay and should not be seen as a cure although Dr Wungki Park (Memorial Sloan Kettering Cancer Centre in New York) who presented the findings on the drug, said he had never seen so many tumours disappear in patients whose cancer had spread and said “ that’s closest to complete remission … it’s incredible”.

  • A gastrointestinal cancer specialist at the University of Arizona, is reported to have “started crying in the clinic” when she read the results.

To date these trials are said to have been for Pancreatic ductal adenocarcinoma (PDAC), i.e. what everyone thinks when they use or hear the term “pancreatic cancer”. There’s no evidence that any pancreatic Neuroendocrine Neoplasm patients were treated or allowed to participate. If you think about it, including pancreatic NETs would skew the data.   The trial is entitled “Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)” NCT07491445

This is comforting news given that half of all people diagnosed with pancreatic cancer die within three months. Among those whose cancer has spread to other organs, only about 3 per cent survive for five years.

Read more:

Clinical Trials Website for Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303) 106 locations across the world – ClinicalTrials.gov ID NCT07491445

Original clinical trial for the pill treatment only Daraxonrasib – Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASsolute 302) – https://clinicaltrials.gov/study/NCT06625320 no longer recruiting.

Credit Pancreatic Cancer Action UK


Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.

Finally

Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product.  Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document.   Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET


Click here to enter Ronny’s Clinical Trials Archive


Thanks for reading

Ronny

 


Discover more from Ronny Allan - Living with Neuroendocrine Cancer

Subscribe to get the latest posts sent to your email.

By Ronny Allan

Ronny Allan is a 3 x award-winning accredited patient leader advocating internationally for Neuroendocrine Cancer and all other cancer patients generally. Check out his Social Media accounts including Facebook, BlueSky, WhatsApp, Instagram and and X.

I love comments - feel free!

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Posts

Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.